Fintel reports that on December 30, 2024, HC Wainwright & Co. initiated coverage of Artiva Biotherapeutics (NasdaqGM:ARTV) with a Buy recommendation.
Analyst Price Forecast Suggests 103.71% Upside
As of December 23, 2024, the average one-year price target for Artiva Biotherapeutics is $21.68/share. The forecasts range from a low of $18.18 to a high of $24.15. The average price target represents an increase of 103.71% from its latest reported closing price of $10.64 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual non-GAAP EPS is -5.20.
What is the Fund Sentiment?
There are 108 funds or institutions reporting positions in Artiva Biotherapeutics. This is an increase of 102 owner(s) or 1,700.00% in the last quarter. Average portfolio weight of all funds dedicated to ARTV is 0.24%, an increase of 26.81%. Total shares owned by institutions increased in the last three months by 14,267.58% to 21,503K shares.
What are Other Shareholders Doing?
Ra Capital Management holds 9,853K shares representing 40.57% ownership of the company.
5AM Venture Management holds 2,353K shares representing 9.69% ownership of the company.
VR Adviser holds 1,610K shares representing 6.63% ownership of the company.
venBio Partners holds 1,520K shares representing 6.26% ownership of the company.
Capital World Investors holds 915K shares representing 3.77% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
